A Type III CRISPR Ancillary Ribonuclease Destroys Its Cyclic Oligoadenylate Activator

Januka S. Athukoralage, Shirley Graham, Sabine Grüschow, Christophe Rouillon1 and Malcolm F. White

Biomedical Sciences Research Complex, School of Biology, University of St Andrews, North Haugh, St Andrews, Fife KY16 9ST, UK

Correspondence to Malcolm F. White: mfw2@st-andrews.ac.uk
https://doi.org/10.1016/j.jmb.2019.04.041
Edited by Konstantin Severinov

Abstract

Cyclic oligoadenylate (cOA) secondary messengers are generated by type III CRISPR systems in response to viral infection. cOA allosterically activates the CRISPR ancillary ribonucleases Csx1/Csm6, which degrade RNA non-specifically using a HEPN (Higher Eukaryotes and Prokaryotes, Nucleotide binding) active site. This provides effective immunity but can also lead to growth arrest in infected cells, necessitating a means to deactivate the ribonuclease once viral infection has been cleared. In the crenarchaea, dedicated ring nucleases degrade cA₄ (cOA consisting of 4 AMP units), but the equivalent enzyme has not been identified in bacteria. We demonstrate that, in Thermus thermophilus HB8, the uncharacterized protein TTHB144 is a cA₄-activated HEPN ribonuclease that also degrades its activator. TTHB144 binds and degrades cA₄ at an N-terminal CARF (CRISPR-associated Rossman fold) domain. The two activities can be separated by site-directed mutagenesis. TTHB144 is thus the first example of a self-limiting CRISPR ribonuclease.

© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

The CRISPR system provides prokaryotes with adaptive immunity against mobile genetic elements (reviewed in Refs. [1–3]). Type III (Csm/Cmr) CRISPR effector complexes harbor two nuclease activities for defense against mobile genetic elements: cleavage of foreign “target” RNA by the Cas7 subunit and degradation of single-stranded DNA by the HD nuclease domain (reviewed in Refs. [4,5]). In addition, effector complexes produce cyclic oligoadenylate (cOA) anti-viral signaling molecules that activate CRISPR ancillary proteins to potentiate the immune response [6,7]. On target RNA binding, the cyclase domain of the Cas10 subunit polymerises ATP into cOA, which consist of 3–6, 5’ to 3’-linked AMP subunits [6–9]. cOA acts as an “alarm signal” within cells and strongly stimulates the activity of the CRISPR ancillary ribonucleases Csx1 and Csm6 [6–8]. Csx1/Csm6 family proteins consist of a CARF (CRISPR-associated Rossmann fold) domain that binds cOA and a HEPN (Higher Eukaryotes and Prokaryotes Nucleotide binding) domain that possesses weak ribonuclease activity in the absence of cOA [10,11]. Once stimulated by cOA, the non-specific RNA degradation activity of the Csm6 ribonuclease impacts both viral and cell growth [12]. Therefore, to recover from viral infection, cells require a mechanism for the removal of cOA. Sulfolobus solfataricus (Sso) encodes dedicated ring nucleases, which degrade the cyclic tetra-adenylate (cA₄) activator and deactivate Csx1 [13]. Thus far, ring nucleases have only been identified in the crenarchaea, and, as highlighted by Mo and Marraffini [14], the enzyme(s) responsible for cOA degradation in bacteria remains unknown. The type III CRISPR system of the bacterium Thermus thermophilus also encodes an uncharacterized CARF domain-containing protein, TTHB144, which was reported to be Csm6-like [17]. Here we report that TTHB144 is also a potent CRISPR ancillary HEPN ribonuclease activated by cA₄. Furthermore,
the enzyme degrades cA4 using its CARF domain. This enzyme therefore represents the first known example of a C0A dependent enzyme that degrades its own activator.

Results and Discussion

The *T. thermophilus* HB8 type III CRISPR locus encodes three CARF domain containing proteins, TTHB144, TTHB152 and TTHB155 (Fig. 1a). A x-ray crystal structure is available for TTHB152 (PDB: 5FSH) revealing a dimeric protein consisting of N-terminal CARF and C-terminal HEPN domains [10]. We modeled the structure of TTHB144 using the Phyre2 server [18], using TTHB152 as a template, and modeled cA4 into the electropositive pocket within the dimeric CARF domain (Fig. 1). Multiple sequence alignment identified highly conserved arginine and histidine residues within the HEPN domain characteristic of the Rx4-6H motif of HEPN nucleases [19]. Furthermore, we observed conserved lysine (K94) and threonine (T10/T11) residues within the ligand binding pocket of the CARF domain. By analogy with the ring nuclease Sso2081 [13], residues K94 and T10/T11 are suitably positioned to interact with cA4.

![Type III CRISPR locus of *Thermus thermophilus* HB8](image)

(a) Gene neighborhood of *TTHB144* encoded on plasmid pTT27. Three genes encoding CARF domain-containing proteins (shown in purple) are present in the type III CRISPR locus of TTHB. TTHB152 is a Csm6 family protein, while TTHB144 and TTHB155 are hypothetical proteins of unknown function. (b) TTHB144 structure modeled using Phyre2. Each subunit of the predicted homodimer is shown by a different color (blue or cream). The highly conserved residues Thr-11, Lys-94 and His-368 are shown. (c) cA4 modeled into the CARF domain of TTHB144. Lys-94 is situated centrally beneath the cA4 molecule, and the side-chain of Thr-11 is suitably positioned to interact with cA4.

![Fig. 1. Type III CRISPR locus of *T. thermophilus* HB8 (*TTHB*) and model structure of TTHB144 with cA4 bound.](image)
the cA4 ligand. Consequently, we constructed a synthetic gene encoding TTHB144, expressed the protein in *Escherichia coli* using the plasmid pEV5-hisTEV [20] and purified the recombinant protein using immobilised metal affinity and size exclusion chromatography, using methods described previously [21]. Site-directed protein variants were constructed and purified as for the wild-type enzyme.

TTHB144 exhibited potent ribonuclease activity in the presence of cA4 and degraded RNA non-specifically (Fig. 2a). The H368A variant, targeting the HEPN active site, had no RNase activity, confirming that TTHB144 is a canonical HEPN ribonuclease. The T10A/T11A variant was still an active cA4-dependent ribonuclease, but the K94A variant was inactive, suggesting that cA4 no longer binds to activate the ribonuclease.

Subsequently, we assayed the rate of RNA degradation by TTHB144 under single-turnover conditions. TTHB144 fully degraded the RNA within 15 s (Fig. 2b), suggesting a lower limit of 5–10 min⁻¹ for the catalytic rate constant. In addition, using the RNaseAlert™ fluorimetric assay system (Integrated DNA Technologies, USA) [6], we followed cA4-activated RNA cleavage by TTHB144 in a continuous assay (Fig. 2c). Consistent with observations made for other CRISPR ancillary ribonucleases such as *Enterococcus italicus* Csm6, *Streptococcus thermophilus* Csm6 and TTHB152 [10], this assay revealed weak TTHB144 ribonuclease activity, which was greatly enhanced by the addition of cA4.

To investigate whether TTHB144 degraded cA4, we incubated the wild-type protein with radiolabeled cA4 generated using the *S. solfataricus* type III-D Csm complex [21]. TTHB144 degraded cA4 to generate a slower migrating product on denaturing polyacrylamide gel electrophoresis (PAGE) (Fig. 2d), which we have previously identified as diadenylate containing a 5′ hydroxyl moiety and a 2′,3′-cyclic phosphate (A₂ > P) [13]. We verified this observation by high-resolution liquid chromatography–mass spectrometry, by comparison of cA4 degradation products with oligoadenylate standards generated using the *E. coli* MazF toxin, as described previously [21]. Similar to the *S. solfataricus* ring nucleases, TTHB144 degraded cA4 to yield an A₄ > P intermediate and A₂ > P product (Fig. 2e).

Subsequently, we evaluated cA4 degradation by TTHB144 CARF and HEPN domain variants. TTHB144 H368A, which has no ribonuclease activity, degraded cA4 similarly to wild-type protein, ruling out a role for the HEPN domain in cA4 degradation. However, cA4 degradation was abolished in the K94A variant and impaired in the T10A/T11A variant (Fig. 2d), suggesting a role for the CARF domain in this reaction. To confirm this hypothesis, we quantified the single-turnover rates of cA4 degradation by TTHB144 and its active site variants. The wild-type and H368A variant degraded cA4 at rates of 0.011 ± 0.004 and 0.013 ± 0.002 min⁻¹, respectively (Fig. 3) allowing us to definitively rule out the HEPN domain as the site of cA4 degradation. The K94A variant was inactive, with no cA4 cleavage detectable over 2 h, while the T10A/T11A variant, which remains a cA4-activated HEPN ribonuclease (Fig. 2a), exhibited a ~12-fold decrease (k = 0.001 ± 0.002 min⁻¹) in cA4 cleavage rate compared to the wild-type protein. The rate of RNA degradation (~5–10 min⁻¹) thus appeared to exceed the rate of cA4 cleavage by approximately 3 orders of magnitude. Consequently, we investigated whether RNA binding at the HEPN domain stimulated cA4 degradation by the CARF domain by including unlabeled RNA in a cA4 degradation assay. TTHB144 degraded cA4 at a rate (0.010 ± 0.042 min⁻¹) similar to cA4 degradation in the absence of RNA, suggesting that RNA binding at the HEPN domain does not affect cA4 degradation at the CARF domain.

To examine cA4 binding by the wild-type and variant enzymes, we carried out gel electrophoretic mobility shift assays with ³²P-labeled cA4 (Fig. 3c). The wild-type protein bound the cA4 ligand at protein dimer concentrations as low as 100 nM, with 100% binding at 1 μM protein. In contrast, neither the T10A/T11A nor the K94A variants yielded detectable cA4 binding at protein dimer concentrations up to 20 μM. The highly conserved lysine residue K94 is clearly crucial for cA4 binding, and may also play a catalytic role during cA4 degradation. The T10 and T11 residues, which sit at the rim of the cA4 binding site, are also clearly important for cA4 binding, although the T10A/T11A variant does retain the ability to degrade (and therefore bind) cA4 at a reduced level. Hence, the TTHB144 cA4 binding and cleavage mechanism may be similar to that of the crenarchaeal ring nuclease Sso2081, where the equivalent residues, S11 and K106, have been shown to be important for cA4 binding and/or cleavage [13].

**Conclusions**

TTHB144 is the first CARF family protein identified to harbor both cA4 degradation activity and ribonuclease activity. The single-turnover rate of cA4 degradation by TTHB144 at 70 °C is slow: comparable to that of the less active *S. solfataricus* dedicated ring nuclease, Sso1393 [13]. This slow rate of cA4 degradation may function as a built-in control mechanism to limit the extent of ribonuclease activity. Faster rates of cA4 degradation could disable this arm of type III CRISPR-mediated immunity. *Streptococcus epidermidis* Csm6 activity during type III immunity has been shown to cause cell growth arrest [12], and self-limiting enzymes may be crucial for cell recovery following clearance of invading genetic entities in bacteria that do not have dedicated ring nucleases.
Fig. 2. RNA degradation and cA₄ cleavage occur in separate domains of TTHB144. (a) Phosphorimage of denaturing PAGE visualizing the degradation of 50 nM radiolabeled A₁ RNA, as previously described [21], by TTHB144 (0.5 μM dimer), its CARF domain variants K94A and T10A/T11A and the HEPN domain variant H368A. The reaction was incubated at 70 °C for 60 min in pH 8.0 buffer containing 20 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA and 3 units SUPERase•In™ inhibitor, before quenching by phenol–chloroform extraction. RNA was cleaved by wild-type (wt) protein and the T10A/T11A variant in the presence of 1 μM cA₄, but not by the K94A or H368A variants. (b) Phosphorimage of denaturing PAGE visualizing degradation of 50 nM radiolabeled RNA by TTHB144 (1 μM dimer) when incubated with 20 μM cA₄ at 70 °C. Control reactions incubating RNA with buffer (c1) or RNA with protein in the absence of cA₄ (c2) are shown. All of the substrate RNA was degraded within 15 s (lane 3). (c) Plot of fluorescence emitted when RNaseAlert™ substrate (1.5 μM; Integrated DNA Technologies) was degraded by 125 nM dimer TTHB144 in the absence or presence of 500 nM cA₄ at 50 °C. Fluorimetry was carried out in a Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies) with excitation and emission wavelengths set to 490 and 520 nm, respectively. (d) Phosphorimage of denaturing PAGE visualizing degradation of 400 nM radiolabeled cA₄ generated using SsoCsm complex, as previously described [21], by TTHB144 (4 μM dimer) and variants at 70 °C for 120 min. cA₄ was degraded to a slower migrating product. (e) High-resolution liquid chromatography mass spectrometry of cA₄ produced using the SsoCsm complex and cleavage products generated on incubation with TTHB144 (40 μM dimer) at 70 °C. cA₄ (~16 μM; top panel) was degraded to intermediate and product species (middle panel) with identical retention times to A₄ > P and A₂ > P, respectively (bottom panel). A₄ > P and A₂ > P standards were generated using the E. coli MazF toxin as previously described [8].
Therefore, the amalgamation of a HEPN ribonuclease and a ring nuclease into a single self-limiting enzyme may help decrease the toxicity associated with non-specific RNA cleavage in type III CRISPR systems.

Fig. 3. cA4 binding and cleavage by wild-type and variant TTHB144 enzymes. (a) Panels are phosphorimages of denaturing PAGE visualizing degradation of 200 nM radiolabeled cA4 by TTHB144 and variants (8 μM dimer) at 70 °C. cA4 is degraded to A2-P. Time in minutes is indicated. Protein and radiolabeled cA4 were incubated in pH 8.0 buffer containing 20 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA and 3 units SUPERase•In™ inhibitor, and reactions were quenched at the indicated time-points by phenol–chloroform extraction. A cA4 degradation assay was also carried out in the presence of 1 μM A1 RNA in order to evaluate the effect of RNA binding and cleavage at the HEPN active site on cA4 degradation at the CARF domain. (b) Plot of the fraction of cA4 cut versus time, generated by quantifying the densiometric signals from the phosphorimages depicted in panel a. All data points are the average of at least three technical replicates and are fitted to an exponential rise equation to derive the rate of cA4 degradation, as described previously [21]. Data points for TTHB144 are the average of six replicates encompassing two biological replicates with three technical replicates for each. Error bars show the standard deviation of the mean. (c) Electrophoretic mobility shift assay of radioactively-labeled cOA generated by the S. solfataricus Csm complex. cA4 is indicated; minor bands correspond to linear and cyclic byproducts of the reaction. cA4 (20 nM) was incubated with TTHB144 or variants T10A/T11A or K94A (0.1, 1, 10 or 20 μM protein dimer) in buffer containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl and 2 mM MgCl2 supplemented with 2 μM Ultrapure Bovine Serum Albumin (Invitrogen) for 10 min at 25 °C. A reaction volume equivalent of 20% (v/v) glycerol was then added prior to loading the samples on a 15% polyacrylamide, 1 x TBE gel. Electrophoresis was carried out at 25 °C and 200 V.

Acknowledgments

This work was funded by a grant from the Biotechnology and Biological Sciences Research Council (Grant REF BB/S000313/1 to M.F.W.).
Author Contribution Statement: J.S.A. carried out the investigation and analysis and wrote the original draft of the paper; S.Grü. and S.Gra. contributed to the investigation and analysis; M.F. W. conceptualized and supervised the work. All authors contributed to the review and editing.

Received 14 March 2019; Received in revised form 22 April 2019; Available online 6 May 2019

Keywords: CRISPR; anti-viral signaling; cyclic oligoadenylate; ring nuclease, Thermus thermophilus

Present address: C. Rouillon, Max Planck Unit for the Science of Pathogens, Charitéplatz 1, 10117 Berlin, Germany.

Abbreviations used: CARF, CRISPR-associated Rossman fold; HEPN, Higher Eukaryotes and Prokaryotes Nucleotide binding; COA, cyclic oligoadenylate; cA4, cyclic tetra-adenylate; TTHB, Thermus thermophilus HB8.

References

[1] R. Barrangou, L.A. Marraffini, CRISPR–cas systems: prokaryotes upgrade to adaptive immunity, Mol. Cell. 54 (2014) 234–244.
[2] E.V. Koonin, K.S. Makarova, Mobile genetic elements and evolution of CRISPR–Cas systems: all the way there and back, Genome Biol. Evol. 9 (2017) 2812–2825.
[3] F. Hille, H. Richter, S.P. Wong, M. Bratović, R. Sarah, E. Charpentier, The biology of CRISPR–Cas: backward and forward, Cell. 172 (2018) 1239–1259.
[4] G. Tamulaitis, Č. Venclovas, V. Siksnys, Type III CRISPR–Cas immunity: major differences brushed aside, Trends Microbiol. 25 (2017) 49–61.
[5] N.C. Pyenson, L.A. Marraffini, Type III CRISPR–Cas systems: when DNA cleavage just isn’t enough, Curr. Opin. Microbiol. 37 (2017) 150–154.
[6] O. Niewoehner, C. Garcia-Doval, J.T. Rostol, C. Berk, F. Schwede, L. Bigler, J. Hall, L.A. Marraffini, M. Jinek, Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers, Nature. 548 (2017) 543–548.
[7] M. Kazlauskienė, G. Kostiuk, Č. Venclovas, G. Tamulaitis, V. Siksnys, A cyclic oligonucleotide signaling pathway in type III CRISPR–Cas systems, Science. 357 (2017) 605–609.
[8] C. Rouillon, J.S. Athukorala, S. Graham, S. Grüssow, M.F. White, Control of cyclic oligoadenylate synthesis in a type III CRISPR system, Elife. 7 (2018) 1–25.
[9] Y. Zhang, G. Montoya, S. Stella, K. Sulek, T. Guo, L. Peng-Lundgren, Q. She, W. Han, A. Type, III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding, Nucleic Acids Res. 46 (2018) 10319–10330.
[10] O. Niewoehner, M. Jinek, Structural basis for the endoribonuclease activity of the type III-A CRISPR–associated protein Csm6, RNA. 22 (2016) 318–329.
[11] N.F. Sheppard, C.V.C. Glover, R.M. Tems, M.P. Tems, The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease, RNA. 22 (2016) 216–224.
[12] J.T. Rostol, L.A. Marraffini, Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR–Cas immunity, Nat. Microbiol. 4 (2019) 656–662.
[13] J.S. Athukorala, C. Rouillon, S. Graham, S. Grüssow, M.F. White, Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate, Nature. 562 (2018) 277–280.
[14] C.Y. Mo, L.A. Marraffini, If you’d like to stop a type III CRISPR ribonuclease, then you should put a ring (nuclease) on it, Mol. Cell. 72 (2018) 608–609.
[15] R.H.J. Staals, Y. Zhu, D.W. Taylor, J.E. Kornfeld, K. Shama, A. Barendregt, J.J. Koehorst, M. Vlot, N. Neupane, K. Varossieau, K. Sakamoto, T. Suzuki, N. Dohmae, S. Yokoyama, P.J. Schaap, H. Urlaub, A.R. Heck, E. Nogales, J.A. Doudna, A. Shinkai, J. van der Oost, RNA targeting by the type III-A CRISPR–Cas Cam complex of Thermus thermophilus, Mol. Cell. 56 (2014) 518–530.
[16] T.Y. Liu, A.T. Lavarone, J.A. Doudna, RNA and DNA targeting by a reconstituted Thermus thermophilus Type III-A CRISPR–Cas system, PLoS One. 12 (2017), e0170552.
[17] S.A. Shah, O.S. Alkhnbashi, J. Behler, W. Han, Q. She, W.R. Hess, R.A. Garrett, R. Backofen, Comprehensive search for accessory proteins encoded with archaeal and bacterial type III CRISPR–cas gene cassettes reveals 39 new cas gene families, RNA Biol. (2018) 1–13.
[18] L.A. Kelley, S. Mezulis, C.M. Yates, M.N. Wass, M.J.E. Sternberg, The Phyre2 web portal for protein modeling, prediction and analysis, Nat. Protoc. 10 (2015) 845–858.
[19] V. Anantharaman, K.S. Makarova, A.M. Burroughs, E.V. Koonin, R.H.J. Staals, Y. Zhu, D.W. Taylor, J.E. Kornfeld, K. Sharma, A. Type, III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding, Nucleic Acids Res. 46 (2018) 10319–10330.
[20] O. Niewoehner, M. Jinek, Structural basis for the endoribonuclease activity of the type III-A CRISPR–associated protein Csm6, RNA. 22 (2016) 318–329.
[21] N.F. Sheppard, C.V.C. Glover, R.M. Tems, M.P. Tems, The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease, RNA. 22 (2016) 216–224.
[22] J.T. Rostol, L.A. Marraffini, Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR–Cas immunity, Nat. Microbiol. 4 (2019) 656–662.
[23] J.S. Athukorala, C. Rouillon, S. Graham, S. Grüssow, M.F. White, Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate, Nature. 562 (2018) 277–280.
[24] C.Y. Mo, L.A. Marraffini, If you’d like to stop a type III CRISPR ribonuclease, then you should put a ring (nuclease) on it, Mol. Cell. 72 (2018) 608–609.
[25] R.H.J. Staals, Y. Zhu, D.W. Taylor, J.E. Kornfeld, K. Shama, A. Barendregt, J.J. Koehorst, M. Vlot, N. Neupane, K. Varossieau, K. Sakamoto, T. Suzuki, N. Dohmae, S. Yokoyama, P.J. Schaap, H. Urlaub, A.R. Heck, E. Nogales, J.A. Doudna, A. Shinkai, J. van der Oost, RNA targeting by the type III-A CRISPR–Cas Cam complex of Thermus thermophilus, Mol. Cell. 56 (2014) 518–530.
[26] T.Y. Liu, A.T. Lavarone, J.A. Doudna, RNA and DNA targeting by a reconstituted Thermus thermophilus Type III-A CRISPR–Cas system, PLoS One. 12 (2017), e0170552.
[27] S.A. Shah, O.S. Alkhnbashi, J. Behler, W. Han, Q. She, W.R. Hess, R.A. Garrett, R. Backofen, Comprehensive search for accessory proteins encoded with archaeal and bacterial type III CRISPR–cas gene cassettes reveals 39 new cas gene families, RNA Biol. (2018) 1–13.
[28] L.A. Kelley, S. Mezulis, C.M. Yates, M.N. Wass, M.J.E. Sternberg, The Phyre2 web portal for protein modeling, prediction and analysis, Nat. Protoc. 10 (2015) 845–858.
[29] V. Anantharaman, K.S. Makarova, A.M. Burroughs, E.V. Koonin, R.H.J. Staals, Y. Zhu, D.W. Taylor, J.E. Kornfeld, K. Sharma, A. Type, III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding, Nucleic Acids Res. 46 (2018) 10319–10330.
[30] O. Niewoehner, M. Jinek, Structural basis for the endoribonuclease activity of the type III-A CRISPR–associated protein Csm6, RNA. 22 (2016) 318–329.